Table 1.

Patient Medication Implementation in 2020 and 2019 Using the Clean Database

EM Database 2020 (n = 118)
All Patients (n = 118)
Periods	Implementation				Odds Ratio
	Estimate	95% CI			Estimate	95% CI		p-value
Beforea	0.903	0.869		0.929	NA
Duringb	0.901	0.863		0.929	0.979	0.835	1.147	0.789
Afterc	0.895	0.856		0.923	0.911	0.787	1.056	0.217
Patients with cancer (n = 10)
Beforea	0.964	0.889		0.989	NA
Duringb	0.962	0.891		0.987	0.945	0.755	1.182	0.619
Afterc	0.942	0.821		0.983	0.610	0.512	0.726	<0.001g
Patients with diabetic kidney disease (n = 25)
Beforea	0.972	0.948		0.985	NA
Duringb	0.962	0.931		0.979	0.731	0.485	1.100	0.133
Afterc	0.960	0.932		0.977	0.701	0.462	1.063	0.094
Patients with HIV (n = 61)
Beforea	0.892	0.842		0.928	NA
Duringb	0.905	0.853		0.939	1.146	0.959	1.368	0.133
Afterc	0.893	0.840		0.930	1.008	0.822	1.237	0.938
Miscellaneous patients (n=22)
Beforea	0.861	0.765		0.922
Duringb	0.828	0.706		0.907	0.781	0.534	1.140	0.200
Afterc	0.835	0.713		0.911	0.818	0.633	1.056	0.124
EM database 2019 (n = 61)
All patients (n = 61)
Periods	Implementation				Odds Ratio
	Estimate		95% CI		Estimate	95% CI		p-value
Winterd	0.922		0.894	0.942	NA
Springe	0.909		0.873	0.936	0.852	0.706	1.029	0.097
Summerf	0.895		0.860	0.923	0.728	0.596	0.891	0.002

Notes: ^aFrom December 1, 2019 to March 15, 2020; ^bFrom March 16 to June 7, 2020; ^cFrom June 8 to September 30, 2020; ^dFrom December 1, 2018 to March 15, 2019; ^eFrom March 16 to June 7, 2019; ^fFrom June 8 to September 30, 2019; ^gThis result is not interpretable as only 5/10 (50%) patients with cancer were still using the EM on September 30, 2020.

Abbreviation: NA, not applicable (reference period).